FDA OKs Daiichi antibody-drug conjugate for HER2+ breast cancer

The FDA approves Daiichi Sankyo’s (OTCPK:DSKYF) antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more prior lines of HER2-based therapies.

HER2+ breast cancer-related tickers: MacroGenics (MGNX -1.6%), Roche (OTCQX:RHHBY +1.4%), Seattle Genetics (SGEN +2%), AstraZeneca (AZN +1.4%), Puma Biotechnology (PBYI -4.7%), Mustang Bio (MBIO +1.5%)

https://seekingalpha.com/news/3527927-fda-oks-daiichi-antibody-drug-conjugate-for-her2-breast-cancer